Premium
High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival
Author(s) -
Laupeze B.,
Amiot L.,
Drenou B.,
Bernard M.,
Branger B.,
Grosset J. M.,
Lamy T.,
Fauchet R.,
Fardel O.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.0007-1048.2002.03350.x
Subject(s) - medicine , chemotherapy , p glycoprotein , multiple drug resistance , myeloid leukemia , myeloid leukaemia , cd34 , myeloid , gastroenterology , haematopoiesis , efflux , immunology , oncology , drug resistance , stem cell , biology , genetics , microbiology and biotechnology
Summary. Multidrug resistance protein (MRP) activity was investigated in 44 newly diagnosed acute myeloid leukaemia (AML) patients using a functional assay based on efflux of carboxy‐2′,7′‐dichlorofluorescein, an anionic dye handled by both MRP1 and MRP2. Elevated MRP transport was detected in 29% of cases, but was not significantly correlated with sex, age, white blood cell count at diagnosis or karyotype. In contrast, it was associated with secondary AML ( P = 0·002), CD34 positivity ( P = 0·041) and P‐glycoprotein activity ( P = 0·01). There was a lower rate of complete remission in MRP‐positive patients versus MRP‐negative patients (23% versus 81%; P = 0·001); overall survival was also better for MRP‐negative patients ( P = 0·004). These data indicate a probable role for MRP activity in the clinical outcome of AML.